loading
Precedente Chiudi:
$3.24
Aprire:
$3.21
Volume 24 ore:
793.17K
Relative Volume:
1.27
Capitalizzazione di mercato:
$206.45M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-5.7054
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
+5.06%
1M Prestazione:
-26.14%
6M Prestazione:
-57.89%
1 anno Prestazione:
+127.37%
Intervallo 1D:
Value
$3.15
$3.32
Intervallo di 1 settimana:
Value
$3.02
$3.365
Portata 52W:
Value
$1.39
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Nome
Corvus Pharmaceuticals Inc
Name
Telefono
(650) 900-4520
Name
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Name
Dipendente
31
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
CRVS's Discussions on Twitter

Confronta CRVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
3.185 206.45M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.75 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.78 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.54 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
230.40 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
228.75 26.16B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-02 Iniziato H.C. Wainwright Buy
2023-08-18 Iniziato Oppenheimer Outperform
2021-12-01 Ripresa Jefferies Buy
2021-05-27 Iniziato Cantor Fitzgerald Overweight
2021-02-10 Downgrade Mizuho Buy → Neutral
2019-09-12 Iniziato Mizuho Buy
2019-05-29 Iniziato ROTH Capital Buy
2017-08-24 Aggiornamento Credit Suisse Underperform → Neutral
2017-05-01 Downgrade Credit Suisse Neutral → Underperform
2016-04-18 Iniziato Credit Suisse Outperform
2016-04-18 Iniziato Guggenheim Buy
Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

pulisher
01:05 AM

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister

01:05 AM
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints New Director to Board - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - TradingView

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN

Apr 07, 2025
pulisher
Mar 29, 2025

Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st

Mar 27, 2025
pulisher
Mar 27, 2025

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable

Mar 27, 2025
pulisher
Mar 26, 2025

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus: Q4 Earnings Snapshot - Greenwich Time

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq

Mar 25, 2025
pulisher
Mar 23, 2025

CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 21, 2025

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter

Mar 21, 2025
pulisher
Mar 20, 2025

Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 19, 2025
pulisher
Mar 19, 2025

Corvus Pharma Reveals Autoimmune Pipeline Strategy at Major HC Wainwright Conference - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times

Mar 18, 2025
pulisher
Mar 17, 2025

Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan

Mar 17, 2025
pulisher
Mar 16, 2025

Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday - The AM Reporter

Mar 16, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian

Mar 12, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News

Mar 12, 2025
pulisher
Mar 03, 2025

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha

Mar 03, 2025
pulisher
Feb 26, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter

Feb 26, 2025

Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Capitalizzazione:     |  Volume (24 ore):